An open study of lamivudine treatment in adult HBeAg negative (presumed pre-core mutant) chronic hepatitis B patients in Iran

Trial Profile

An open study of lamivudine treatment in adult HBeAg negative (presumed pre-core mutant) chronic hepatitis B patients in Iran

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Sep 2006

At a glance

  • Drugs Lamivudine (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 29 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top